Effects of IGBP1 on proliferation and tamoxifen resistance in ER-positive breast cancer

Tan Wenhao; Liu Shengchun

doi:10.13406/j.cnki.cyxb.003620

您当前的位置：

首页 >

文章列表页 >

Effects of IGBP1 on proliferation and tamoxifen resistance in ER-positive breast cancer

Clinical research | 更新时间：2025-10-23

- Effects of IGBP1 on proliferation and tamoxifen resistance in ER-positive breast cancer
- Journal of Chongqing Medical University Vol. 49, Issue 11, Pages: 1465-1473(2024)
- 作者机构：
  
  重庆医科大学附属第一医院乳腺甲状腺外科，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003620
  CLC： R737.9
- Received：31 August 2024，
  
  Revised：2024-09-22，
  
  Accepted：25 September 2024，
  
  Published：28 November 2024
- 稿件说明：
移动端阅览
谭文浩,刘胜春.IGBP1对ER阳性乳腺癌增殖和他莫昔芬耐药的影响[J].重庆医科大学学报,2024,49(11):1465-1473.

Tan Wenhao,Liu Shengchun.Effects of IGBP1 on proliferation and tamoxifen resistance in ER-positive breast cancer[J].Journal of Chongqing Medical University,2024,49(11):1465-1473.
谭文浩,刘胜春.IGBP1对ER阳性乳腺癌增殖和他莫昔芬耐药的影响[J].重庆医科大学学报,2024,49(11):1465-1473. DOI： 10.13406/j.cnki.cyxb.003620.

Tan Wenhao,Liu Shengchun.Effects of IGBP1 on proliferation and tamoxifen resistance in ER-positive breast cancer[J].Journal of Chongqing Medical University,2024,49(11):1465-1473. DOI： 10.13406/j.cnki.cyxb.003620.

摘要

目的

通过CRISPR Screen正向基因筛选技术，筛选出他莫昔芬耐药靶点基因免疫球蛋白结合蛋白1（immunoglobulin binding protein 1，IGBP1）。验证IGBP1在临床乳腺癌患者肿瘤组织中是否高表达，并探讨IGBP1对雌激素受体阳性（ER

）乳腺癌细胞增殖、细胞周期和耐药性等表型的影响，为诊断和治疗提供潜在靶点。

方法

应用公共数据库分析IGBP1在乳腺癌患者肿瘤组织及配对癌旁组织中的表达是否有所不同。Kaplan-Meier Plotter用于预测IGBP1对乳腺癌患者总体生存率（the overall survival，OS）是否有所影响。应用慢病毒感染ER

乳腺癌细胞，再进行功能实验验证IGBP1过表达及敲低对ER

乳腺癌细胞增殖、细胞周期和耐药性的影响。最后用公共数据库鉴定出可能与IGBP1正、负相关的基因。

结果

公共数据库的结果表明，IGBP1在乳腺癌组织中高表达。生存分析表明，IGBP1高表达的患者的OS较差。细胞功能实验显示，过表达IGBP1的细胞增殖、细胞周期明显快于对照组细胞，耐药性增强；而敲低IGBP1的结果相反。与IGBP1正相关的基因里有已知的癌基因如NOP53。

结论

IGBP1在ER

乳腺癌中高表达，IGBP1的过表达和敲低均影响ER

乳腺癌细胞系的增殖、细胞周期和耐药性，提示IGBP1在ER

乳腺癌中可能能够改善其耐药，表明IGBP1可能作为ER

乳腺癌的潜在治疗靶点之一。

Abstract

Objective

Used CRISPR Screen，a forward gene screening technique，to screen for the tamoxifen-resistant target gene，immunoglobulin binding protein 1（IGBP1）. Then we verified whether IGBP1 was overexpressed in tumor tissues of clinical patients with breast cancer and explored the impact of IGBP1 on cell proliferation，cell cycle，drug resistance，and other phenotypes in patients with estrogen receptor-positive（ER

） breast cancer，with the aim to provide potential targets for the diagnosis and treatment of the disease.

Methods

Public databases were used to analyze whether the expression of IGBP1 was different in the tumor tissue and paracancerous tissue of patients with breast cancer. Kaplan Meier Plotter was used to predict the impact of IGBP1 on the overall survival（OS） of patients with breast cancer. The im

pact of IGBP1 overexpression and knockdown on cell proliferation，cell cycle，and drug resistance of ER

breast cancer cells was verified using functional experiments following ER

breast cancer cell infection with lentivirus. Finally，public databases were used to identify genes that may be positively or negatively correlated with IGBP1.

Results

The results from the public databases showed that IGBP1 was highly expressed in breast cancer tissue. Survival analysis showed that patients with high expression of IGBP1 had poorer OS. Cell functional experiments showed that cells overexpressing IGBP1 had significantly faster proliferation and cell cycle and increased drug resistance than control cells，while the results were opposite for cells with IGBP1 knockdown. There were known oncogenes such as NOP53 among genes that were positively correlated with IGBP1.

Conclusion

IGBP1 is highly expressed in ER

breast cancer. Either overexpression or knockdown of IGBP1 will affect the proliferation，cell cycle，and drug resistance of ER

breast cancer cell lines，suggesting that IGBP1 may improve drug resistance in ER

breast cancer and thus be one of the potential therapeutic targets for ER

breast cancer.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 ．

Curigliano G ， Burstein HJ ， Gnant M ， et al . Understanding breast cancer complexity to improve patient outcomes：the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 [J ] . Ann Oncol ， 2023 ， 34 （ 11 ）： 970 - 986 ．

Perou CM ， Sørlie T ， Eisen MB ， et al . Molecular portraits of human breast tumours [J ] . Nature ， 2000 ， 406 （ 6797 ）： 747 - 752 ．

Prat A ， Perou CM . Deconstructing the molecular portraits of breast cancer [J ] . Mol Oncol ， 2011 ， 5 （ 1 ）： 5 - 23 ．

Prat A ， Parker JS ， Fan C ， et al . PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer [J ] . Breast Cancer Res Treat ， 2012 ， 135 （ 1 ）： 301 - 306 .

Prat A ， Parker JS ， Karginova O ， et al . Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer [J ] . Breast Cancer Res ， 2010 ， 12 （ 5 ）： R68 ．

Cancer Genome Atlas Network . Comprehensive molecular portraits of human breast tumours [J ] . Nature ， 2012 ， 490 （ 7418 ）： 61 - 70 ．

Ciriello G ， Gatza ML ， Beck AH ， et al . Comprehensive molecular portraits of invasive lobular breast cancer [J ] . Cell ， 2015 ， 163 （ 2 ）： 506 - 519 ．

Hugh J ， Hanson J ， Cheang MC ， et al . Breast cancer subtypes and response to docetaxel in node-positive breast cancer：use of an immunohistochemical definition in the BCIRG 001 trial [J ] . J Clin Oncol ， 2009 ， 27 （ 8 ）： 1168 - 1176 ．

Vaz-Luis I ， Ottesen RA ， Hughes ME ， et al . Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network：a prospective cohort study [J ] . Breast Cancer Res ， 2012 ， 14 （ 5 ）： R129 ．

Perez EA ， Romond EH ， Suman VJ ， et al . Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer：joint analysis of data from NCCTG N9831 and NSABP B-31 [J ] . J Clin Oncol ， 2011 ， 29 （ 25 ）： 3366 - 3373 ．

Cortazar P ， Zhang LJ ， Untch M ， et al . Pathological complete response and long-term clinical benefit in breast cancer：the CTNeoBC pooled analysis [J ] . Lancet ， 2014 ， 384 （ 9938 ）： 164 - 172 ．

Liedtke C ， Mazouni C ， Hess KR ， et al . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J ] . J Clin Oncol ， 2023 ， 41 （ 10 ）： 1809 - 1815 ．

Hanker AB ， Sudhan DR ， Arteaga CL . Overcoming endocrine resistance in breast cancer [J ] . Cancer Cell ， 2020 ， 37 （ 4 ）： 496 - 513 ．

Will M ， Liang J ， Metcalfe C ， et al . Therapeutic resistance to anti-oestrogen therapy in breast cancer [J ] . Nat Rev Cancer ， 2023 ， 23 （ 10 ）： 673 - 685 ．

Mishra A ， Srivastava A ， Pateriya A ， et al . Metabolic reprograming confers tamoxifen resistance in breast cancer [J ] . Chem Biol Interact ， 2021 ， 347 ： 109602 ．

Onda M ， Inui S ， Maeda K ， et al . Expression and chromosomal localization of the human alpha 4/ IGBP1 gene，the structure of which is closely related to the yeast TAP42 protein of the rapamycin-sensitive signal tr ansduction pathway [J ] . Genomics ， 1997 ， 46 （ 3 ）： 373 - 378 ．

Kong M ， Fox CJ ， Mu J ， et al . The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis [J ] . Science ， 2004 ， 306 （ 5696 ）： 695 - 698 ．

Jiang SC ， Li DJ ， Liang ZB ， et al . High expression of IGBP1 correlates with poor prognosis in esophageal squamous cell carcinoma [J ] . Int J Biol Markers ， 2020 ， 35 （ 1 ）： 33 - 40 ．

Li DP ， Sakashita S ， Morishita Y ， et al . Binding of lactoferrin to IGBP1 triggers apoptosis in a lung adenocarcinoma cell line [J ] . Anticancer Res ， 2011 ， 31 （ 2 ）： 529 - 534 ．

Sato T ， Shiba-Ishii A ， Kim Y ， et al . miR-3941：a novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma [J ] . Cancer Sci ， 2017 ， 108 （ 3 ）： 536 - 542 ．

Sakashita S ， Li DP ， Nashima N ， et al . Overexpression of immunoglobulin（CD79a） binding protein1（IGBP-1） in small lung adenocarcinomas and its clinicopathological significance [J ] . Pathol Int ， 2011 ， 61 （ 3 ）： 130 - 137 ．

Chen DQ ， Fan YF ， Wan F . LncRNA IGBP1-AS1/miR-24-1/ZIC3 loop regulates the proliferation and invasion ability in breast cancer [J ] . Cancer Cell Int ， 2020 ， 20 ： 153 ．

Szostakowska M ， Trębińska-Stryjewska A ， Grzybowska EA ， et al . Resistance to endocrine therapy in breast cancer：molecular mechanisms and future goals [J ] . Breast Cancer Res Treat ， 2019 ， 173 （ 3 ）： 489 - 497 ．

Kwon OC ， Lee EJ ， Oh JS ， et al . Plasma immunoglobulin binding protein 1 as a predictor of development of lupus nephritis [J ] . Lupus ， 2020 ， 29 （ 6 ）： 547 - 553 ．

Jr Graham JM ， Wheeler P ， Tackels-Horne D ， et al . A new X-linked syndrome with agenesis of the corpus callosum，mental retardation，coloboma，micrognathia，and a mutation in the Alpha 4 gene at Xq13 [J ] . Am J Med Genet A ， 2003 ， 123 （ 1 ）： 37 - 44 ．

Liu M ， Wang YH ， Yang SJ ， et al . Single nucleotide polymorphism array analysis uncovers a large，novel duplication in Xq13.1 in a floppy infant syndrome patient [J ] . Int J Dev Neurosci ， 2019 ， 74 ： 56 - 60 ．

Du HJ ， Huang YZ ， Zaghlula M ， et al . The MID1 E3 ligase catalyzes the polyubiquitination of Alpha4（α4），a regulatory subunit of protein phosphatase 2A（PP2A）：novel insights into MID1-mediated regulation of PP2A [J ] . J Biol Chem ， 2013 ， 288 （ 29 ）： 21341 - 21350 ．

Du HJ ， Massiah MA . NMR studies of the C-terminus of alpha4 reveal possible mechanism of its interaction with MID1 and protein phosphatase 2A [J ] . PLoS One ， 2011 ， 6 （ 12 ）： e28877 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients

Effects of circular RNA hsa_circ_0002185 on cell viability and invasion of breast cancer cells and its mechanism of action

Mechanism of sestrin 3 inhibiting the proliferation of hormone receptor-positive breast cancer and enhancing the sensitivity to endocrine therapy via the mammalian target of rapamycin signaling axis

Endocrine therapy in hormone receptor positive breast cancer

Related Author

Wu Qi

Wang Jianmei

Zhang Jieqiu

Yao Xiaopeng

Shaojie Qin

Mingliang Ning

Qingyuan Liu

Zhenning Tang

Related Institution

Department of Epidemiology and Health Statistics， School of Public Health，Southwest Medical University

Department of Pathology，The Affiliated Hospital of Southwest Medical University

Department of Medical Engineering Technology，School of Medical Information and Engineering，Southwest Medical University

Oncological Surgery Third Department, General Hospital of Ningxia Medical University

School of Laboratory Medicine，Chengdu Medical College

⁰